Ibogaine Hydrochloride

Ibogaine is a naturally occurring indole alkaloid associated with the root bark of Tabernanthe iboga. The broad ibogaine record includes its historical use and the later scientific attention to its psychoactive and pharmacological effects.

Ibogaine hydrochloride, often called ibogaine HCl, is the pharmaceutical-grade crystalline salt form produced through extraction or semisynthesis and conversion to a hydrochloride salt. This form is used when stability and standardized dosing are central research or clinical concerns.

• Free base formulaC₂₀H₂₆N₂O
• Typical research formOral, encapsulated ibogaine HCl
• PharmacologyMultiple receptor and transporter targets
• United States statusSchedule I; not FDA-approved

Its pharmacology is polypharmacologic: ibogaine interacts with opioid receptors, dopamine and serotonin transporters, NMDA receptors, and nicotinic acetylcholine receptors, among other targets. A detailed peer-reviewed pharmacology review describes why that broad activity profile complicates simple claims about one mechanism or one outcome.

Ibogaine HCl has drawn interest because research programs are examining its possible relevance to substance use disorders, trauma-related conditions, and traumatic brain injury. A UCSF account of ibogaine-inspired research illustrates the effort to understand therapeutic signals while developing compounds that may avoid some of ibogaine’s risks.

In the United States, ibogaine remains a Schedule I substance and is not approved by the Food and Drug Administration. The DEA’s scheduling framework is useful context for understanding why research activity does not equal routine legal access or established medical use.

Research interest is not a substitute for evidence of safety, effectiveness, or legal availability.

Policy, trial design, and public discussion can change quickly. For state-level context, the discussion around Texas ibogaine legislation is one example of how research priorities and local policy debates may intersect.

Research discussion should distinguish potential from proof. Adults looking at claims about ibogaine and drug addiction should account for the difference between preliminary findings, observational reports, formal trials, and treatment recommendations.

For a technical description of the salt form and its handling context, ibogaine hydrochloride reference material can help clarify terminology, but it does not replace individualized medical or legal assessment.

Clear information also means respecting context. Questions about ibogaine in Canada may involve a different regulatory environment than questions in the United States, while accounts of an ibogaine trip experience are not equivalent to clinical evidence.

The source material matters as well. Interest in ibogaine plant seeds concerns a botanical starting point, whereas discussion of ibogaine HCl concerns a purified and standardized salt form. These terms should not be treated as interchangeable.

For adults seeking a more structured way to navigate research, regulation, and safety language, the site’s topic-guidance resources organize key questions without promoting unsupervised use. The FDA drug development process offers additional context for why investigational research and approved treatment are distinct stages.